FOLH1 and posterior cortical atrophy: Furthermore, PSMA-targeting ligands have been labeled with nuclides, such as lutetium-177 (177Lu) or actinium-225 (225Ac), with therapeutic purposes, achieving beneficial effects in advanced PCa patients with acceptable toxicity [17,18].